HOW TO PLAY IT

The best way for investors to play the growth in lessinvasive medicine: Focus on companies advancing curative geneediting therapies that forgo surgery altogether. Intellia

Therapeutics is developing a CRISPR/Cas9

injectable therapeutic to target diseased genes, then edit, repair or insert healthy cells. The Cambridge, Massachusetts– based company announced in June

that its singledose treatment for a rare genetic liver disease was highly effective. It was the first clinical data supporting the safe use of genome editing in humans. Intellia lost $46 million during the first quarter of 2021, yet its science could eliminate many invasive

surgeries.

Jon D. Markman

is president of Markman Capital Insight and the editor of Fast Forward Investing.